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Abstract Newborns are exposed to mechanical and oxida-
tive stress during labor and to relative hyperoxia thereafter
during the course of adaptation to the extrauterine con-
ditions. Part of the adaptation mechanism is the rapid
degradation of fetal hemoglobin and the oxidation of its
heme moiety by heme oxygenases (HOs). Heme oxygen-
ase-1 enzyme (HO-1) is the inducible isoform, which is
induced by and protective against oxidative stress. We
hypothesized that HO-1 may play a role in the physiolog-
ical adaptation of newborns. We therefore measured the
HO-1 mRNA expression with cRT-PCR during the first
week after birth in healthy mature and premature newborns.
We found that HO-1 was induced until day 2 or 3 after
birth, but its level had dropped below the birth HO-1 mRNA
level by the end of the first week. HO-1 levels and
inducibility were similar in mature newborns and premature
newborns. The fact that HO-1 was inducible even in
gestation week 26 suggests that HO-1 plays an important
role in the early adaptation processes.
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Abbreviations
CDS coding sequence
cRT-PCR competitive reverse transcriptase polimerase
chain reaction
HGB hemoglobin
HMOX1 heme oxygenase-1 gene
HO-1 heme oxygenase-1 protein
HO-2 heme oxygenase-2 protein
MCV mean corpuscular volume
PLT platelet count
WBC white blood cell count
Introduction
Birth itself causes mechanical and oxidative stress for
newborns. All infants, regardless of gestational age, display
evidence of oxidative stress during the first few days after
birth; this is especially true for premature infants, who have
a much lower antioxidant capacity than that of term babies
[11, 15]. The switch to aerial breathing, the increased
partial O2 concentration and the stress caused by birth
induce many physiological processes, most notably the
neonatal adaptation to the greatly changed conditions.
Part of the adaptation is the rapid degradation of fetal
hemoglobin and the oxidation of its heme moiety by heme
oxygenases (HOs), which are contributing factors in the
development of post parturition hyperbilirubinemia [9].
Although free heme can be cytotoxic directly [1], it can also
become toxic by mediating oxidative stress and inflamma-
tion [4]. HOs catalyze the rate-limiting step in heme
degradation, resulting in the formation of free Fe2+, carbon
monoxide and biliverdin, which is subsequently converted
to bilirubin by biliverdin reductase [8]. Biliverdin and
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bilirubin are themselves potent antioxidants and play a
protective role against oxidative stress [2, 10, 20].
Two functional HO isoforms are known in humans,
HO-1 and HO-2. HO-2 is the constitutional form, while
HO-1 is the form transcriptionally inducible by a variety of
agents, such as heme, oxidants, inflammatory cytokines,
UV irradiation, heavy metals and arsenite [5, 7]. HO-1
plays a cytoprotective role in oxidative stress and heme-
mediated injury [21]. On the other hand, a transiently
enhanced HO-1 mRNA accumulation is a reliable marker
of oxidative stress [12, 18, 23].
Although HO-1 induction may be a general and adaptive
response to oxidant stress, the inducibility of this enzyme in
the early postnatal period remains to be established. We
hypothesized that the enzymatic immaturity of HO-1 or its
regulation system could play a role in the early transitory
adaptation disturbances of premature neonates. According-
ly, we set out to investigate the HO-1 expression in mature
and premature neonates during the first week after birth in
order to estabilish whether the enzyme is inducible and
whether there are any differences between the two groups.
Subject and methods
Patients
A study was carried out to investigate the HO-1 mRNA
levels in mature and premature neonates during the first
week after birth. The two groups of patients consisted of 21
mature (gestation time 37–40 weeks, birth weight median
3,305 g, quartiles 3,060 g, 3,770 g) and 20 premature
neonates (gestation time 26–36 weeks, birth weight median
1,860 g, quartiles 1,450 g, 2,230 g) with transient neonatal
adaptation difficulties. We excluded babies with respiratory
distress, sepsis, positive bacteriology or any serious
complication (intracerebral hemorrhage, necrotizing entero-
colitis, pneumonia, pneumothorax, or any congenital heart
disease). None of the examined patients were on mechan-
ical ventilation (>24 h) and none of them received a blood
transfusion during the investigation period.
The indication of phototeraphy was according to the
practice written in Care of the high-risk neonate [6]. The
patients (mature n=5, premature n=7) requiring photo-
therapy were on intermittent therapy (425–475 nm light/
normal light in 4-h intervals). None of the mature neonates
had to be supplied with extra O2. Ten premature neonates
with a transitory adaptational disturbance were on extra O2
(<24 h). Indication of extra oxygen support was determined
by PaO2 values (the PaO2 levels were kept in the range 40–
60 mmHg in prematures with less than 1,500 g birtweight).
The median of FiO2 values in these patients were 0.4
(quartiles 0.3, 0.6).
Sample collection
Whole blood samples were pipetted in EDTA microtainer
tubes (approx. 200 μl per sample) from fresh whole blood
taken for other necessary routine analysis. For mRNA
analysis, 100 μl was pipetted out immediately into 1 ml of
RNA stabilization reagent. A quantitative blood count was
performed on an ABX Micros 60 hematological automat.
We obtained blood samples from mature newborns in
parallel with the routine serum bilirubin assay: usually 2–3
times from each baby during the first 6 days before they left
the obstetric ward. We obtained blood samples from
premature newborns in parallel with other routine blood
parameter analysis each day following birth.
This study was approved by the Scientific Committee
and the Ethical Council of Szeged University.
RNA extraction and competitive reverse transcriptase
(cRT)-PCR experiments
The mRNA was extracted from 100 μl of venous blood
with the mRNA Isolation Kit for Blood/Bone Marrow
Fig. 1 Part of HMOX1 CDS from exon 3 to 5. HMOX1-T3 and
HMOX1-mut were used to create a PCR product from which we
transcribed our control RNA, the sequence of which differs from that
of wild-type HMOX1 mRNA in only a 20-bp deletion. The mRNA
and control RNA were reverse-transcribed and consecutively ampli-
fied by the same primers HMOX1-F and HMOX1-R
Mature neonates n=21 Premature neonates n=20
Day 1 Day 3 Day 5 Day 1 Day 3 Day 5
Hgb (g/l) 159.6±19.6 155.4±23.1 156.6±29.8 184.8±16.0* 187.0±18.5* 172.7±18.8*
MCV (fl) 110.7±2.9 110.1±4.7 108.4±4.5 109.1±3.8 108.2±3.6 106.2±4.3
PLT (109/l) 187.5±84.1 198.7±79.3 243.1±112.6 233.3±67.4* 248.7±56.7* 280.2±96.6*
WBC (109/l) 14.75±4.80 9.91±4.01 10.1±4.30 19.3±2.56** 10.83±1.77 10.10±2.23
Table 1 Blood count parame-
ters of mature and premature
neonates (mean±SD)
Student’s t-test: *P<0.001;
**P<0.005 healthy premature
vs mature neonates
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(Roche Diagnostics, Mannheim, Germany). Expression of
theheme oxygenase 1 gene (HMOX1) was identified using
cRT-PCR. The competitor RNA was created by in vitro
mutagenesis and transcription with T3 RNA polymerase
(Fermentas, Vilnius, Lithuania) according to Waha et al.
[22]. The primers to generate the competitor were as
follows: HMOX1-T3: 5′-AATTAACCCTCACTAAAGG
GAGACGTTTCTGCTCAACATCCAGCTC-3 ′, and
HMOX1-mut: 5′-CCTGGGAGCGGGTGTTGAGTGG
GGGGCAGAATCTTGCACTTTG-3′. First-strand cDNA
was generated by using the RevertAid™ First Strand
cDNA Synthesis Kit (Fermentas, Vilnius, Lithuania) with
the specific primer of HMOX1-R. The specific oligonucle-
otide primers applied for the PCR reaction were designed to
span exon boundaries, thereby binding only at the cDNA
level (Fig. 1). The PCR amplification was carried out with
the following program: initial denaturation at 94°C for
5 min, followed by 25 cycles of denaturation at 94°C for
20 s, annealing at 61°C for 30 s and extension at 72°C
for 20 s, followed by a final extension at 72°C for 10 min.
The primers were as follows: HMOX1-F: 5′-CGTT
TCTGCTCAACATCCAGCTC-3′, and HMOX1-R: 5′-
CCTGGGAGCGGGTGTTGAGTG-3′. The amplified
cDNAs were examined on 6% polyacrylamide gel and
Fig. 2 Relative HO-1 mRNA levels of all examined patients plotted
against the gestational age during the first 6 days after birth. The filled
triangles mark HO-1 expression data of neonates with extra O2
therapy. The empty squares represent babies without extra O2 therapy.
FiO2 values are shown as medians
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stained with ethidium bromide. The target HMOX1 band
was estimated via the ratio to the competitor by densitom-
etry (AlphaImager™, AlphaEase 5.5). HO-1 mRNA con-
centrations were expressed with reference to the white
blood cell count (WBC); since we did not calculate the
copy number of our control RNA, these are relative values
(we used the same dilutions of control RNA). Control RNA
and mRNA were handled together in the same tubes; their
ratio therefore remained the same throughout the whole
process.
We established a sensitive cRT-PCR method to measure
the mRNA levels of the transcriptionally induced HO-1
from 100 μl of whole blood, which was essential for our
experiments because of the limited amount of sample
available. We followed the HO-1 expression during the
first week after birth in both the mature and the premature
newborns.
Statistical analysis
Clinical data on the patients are reported as means
±standard deviations. Statistical analyses included the
Kruskal-Wallis test and the Student t-test for the analysis
of HO-1 expression changes, and the unpaired t-test with
the Welch correction for analysis of the blood counts of the
premature and mature neonates. The level of statistical
significance for all tests was taken as α=0.05.
Results
The hemoglobin (Hgb), mean corpuscular volume (MCV),
WBC, and platelet count (PLT) for the mature and
premature newborns were in the normal ranges (Table 1)
and their changes during the first week excluded the
presence of severe anemia, sepsis or inflammation.
The HO-1 expressions of all examined patients plotted
against the gestational age are shown in Fig. 2. The relative
HO-1 mRNA levels of the mature and premature neonates
plotted against the days passed after birth are shown in
Fig. 3. The levels and inducibility of HO-1 in the two
groups proved similar although on the second day in
premature neonates HO-1 expression was significantly
higher than that of mature neonates (P<0.05). HO-1
expression was induced on days 2 and 3. Later, the HO-
1 mRNA levels decreased and dropped below the day 1
value by the end of the first week. The serum bilirubin
levels of the mature and premature neonates are shown in
Fig. 4. These levels increased significantly after birth in
both groups, and were the highest on day 5 after birth.
Discussion
The degradation of fetal hemoglobin during the adaptation
after birth leads to an increased release of free heme, which
Fig. 3 Relative HO-1 mRNA
levels during the first week
after birth in healthy mature and
premature neonates. Unpaired
t-test: **P<0.005 day 3 vs day
1; ###P<0.001 last day sample
vs day 3, +P<0.05 2nd day
values of mature vs premature
neonates
Fig. 4 Bilirubin levels during
the first week after birth in
healthy mature and premature
neonates. Unpaired t-test:
**P<0.005 day 5 vs day 1
1036 Eur J Pediatr (2007) 166:1033–1038
is an aggressive oxidative agent. Free heme is a substrate
and inductor of its catabolizing enzyme, HO-1, which is
also expressed in the lympho-, mono- and granulocytes in
blood [13]. HO-1 is transcriptionally induced and we could
therefore apply a sensitive cRT-PCR method to measure the
increased copy number of HO-1 mRNA. The method is
sensitive enough for the quantitative analysis of HO-1
mRNA separated from 100 μl of whole blood.
The one HMOX1-deficient patient described in the
literature suffered from growth failure, anemia, tissue iron
deposition, lymphadenopathy, leukocytosis, and increased
sensitivity to oxidant injury. He ultimately succumbed to a
premature death [24]. In the animal model of HO-1
deficiency, mice lacking the gene frequently die in utero
[14], and those surviving to term display a phenotype
similar to the HO-1-deficient boy. It is also suggested that
HO-1 activity is required for iron reutilization in mammals
[14] for the prevention of abnormal iron accumulation in
hepatic and renal cells, which otherwise contributes to
oxidative damage, tissue injury and chronic inflammation.
Clearly, HO-1 is necessary to the survival of organisms.
It is suggested that even the full-term healthy infants
experience oxidative stress, which resolves only with age
[3]. In our study, we measured an elevated HO-1 expression
level in both mature and premature newborns immediately
after birth which could be sign of oxidative stress. As the
HO-1 levels increased during the following days (Figs. 2,
3), we can conclude that HO-1 is inducible in this early
stage in both premature and mature neonates. The fact that
the induction of HO-1 mRNA and its maximum precede the
maximal bilirubin levels demonstrates that HO-1 is func-
tional and cleaves free heme to biliverdin, CO and Fe2+.
It has been shown that in species in which hemolysis
takes place post parturition, the activity of HO is enhanced
in the early newborn period [9]. The present data are the
first on HO-1 expression in humans after birth, our data
also showed similar induction pattern as observed in
animals [17]. We showed that the inducibility of HO-1
does not depend on the gestational age (Fig. 2). Though
many enzymes show enzyme immaturity in premature
neonates the two groups of patients did not exhibit
differences in HO-1 expression pattern. Our study indicates
that healthy premature neonates (without any organ
manifestation of oxygen radical injury) are prepared to
handle the released heme by the induction of the HO-1
system during neonatal adaptation.
Oxygen radical injury is a common pathogenic mecha-
nism in a number of neonatal diseases, including idiopathic
respiratory distress syndrome, retinopathy of prematurity,
bronchopulmonary dysplasia, subependymal and intraven-
tricular hemorrhage and necrotizing enterocolitis [15, 16].
These disorders display a higher incidence in preterm
infants with deficient antioxidant protective systems [19].
Our study suggests that healthy premature neonates can
handle the the increased heme released during neonatal
adaptation. The question arises of whether the disturbance
of HO-1 inducibility plays a role in premature newborns
with “oxygen radical disease of prematurity”.
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